ENDRA Life Sciences Inc.NDRA

Market cap

$1.93M

P/E ratio

	Dec 31, 2017	Dec 31, 2018	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022
Net loss	-5,376,962	-9,796,261	-13,305,964	-11,725,501	11	13
Depreciation and amortization	61,481	68,316	80,577	99,342	116,238	96,661
Fixed assets write off	-	-	-	-	9,874	1,391
Stock compensation expense including common stock issued for RSUs	-	-	-	-	1	1
Amortization of right of use assets	-	-	-	-	108,177	137,597
Gain on extinguishment of debt	-	-	-	-	308,600	-
Decrease in prepaid expenses	67,497	77,928	-28,675	274,051	957,203	-355,128
Increase in inventory	151,574	155,305	53,998	476,178	694,958	1
Increase in accounts payable and accrued liabilities	528,294	126,368	760,143	-834,990	491,104	111,575
Decrease in lease liability	-	-	-	-	-	-132,330
Net cash used in operating activities	-3,300,914	-7,702,481	-8,588,851	-10,746,595	-11,122,384	-12,769,371
Purchases of fixed assets	-	100,000	43,595	75,333	45,000	202,577
Net cash used in investing activities	-7,862	-100,000	-43,595	-75,333	-45,000	-202,577
Proceeds from warrant exercise	-	-	-	5	3	-
Proceeds from issuance of common stock	9	8	125,000	7	11	8
Net cash provided by financing activities	9	9	8	12	13	8
Net increase (decrease) in cash	-	-	-	-	2	-4,572,436
Interest paid	-	40,085	-	1,920	57,655	59,113
Income tax paid	-	-	-	-	-	-
Deemed dividend	-	-	4	395,551	121,071	-
Conversion of Series A Convertible Preferred Stock	-	-	-	-	-7	-
Stock dividend payable	-	-	-	-	-3,067	7,790
Right of use asset	-	-	34,434	65,907	643,413	505,816
Lease liability	-	-	-	-	650,477	518,147